One of the first studies of cannabinoids in MS model is reported by Lyman et al. in 1989 [100], who demonstrated the effects of daily administration of ∆9-THC, a partial CB1R agonist with limited effects on CB2R, on EAE progression in rats. Here, CNR1 is linked to myeloid sarcoma.